Kathleen Neuzil

Neuzil studied zoology at the University of Maryland, College Park and graduated summa cum laude in 1983.[1] She was a medical student at Johns Hopkins University, where she was a member of Alpha Omega Alpha. She completed her residency at Vanderbilt University, where she specialised in internal medicine in 1987.[1] She was made a Fellow in infectious disease at Vanderbilt University in 1991.[1] After completing her fellowship, Neuzil started a Master of public health and graduated in 1998.[1]

Neuzil works on vaccine development and policy.[2] After her fellowship Neuzil joined the University of Washington School of Medicine, where she served as Director of PATH's Influenza Vaccine Development Project.[3][4] PATH is a Seattle-based nonprofit global health organisation, where Neuzil worked on the rotavirus, human papillomavirus infection (HPV) and Japanese encephalitis vaccines.[5][6] In 2008 Neuzil partnered with Lentigen Corporation to research the pandemic influenza vaccine.[3] Their early work considered the development of Influenza A virus subtype H1N1 and H5N1 virus-like particle pandemic influenza vaccines.[3] Virus-like particle vaccines offer immunogenic, strain-specific recombinant antigens that can be produced at scale.[3] In 2008 Neuzil was made Chair of the Infectious Diseases Society of America Pandemic Influenza Task Force.[1] In 2015 Neuzil joined the University of Maryland School of Medicine.[4][7]

At the Center for Vaccine Development Neuzil has developed and deployed vaccines to protect against a range of diseases including typhoid fever, shigellosis, malaria and cholera.[5][8] She has also considered emerging pathogens such as the Zika and Ebola viruses.[5][9][10] The Center is also part of the Typhoid Vaccine Acceleration Consortium (TyVAC),[11] a collaboration between the Oxford Vaccine Group, University of Maryland School of Medicine Center for Vaccine Development.[12] The typhoid conjugate vaccine created by TyVAC was demonstrated as a cost-effective strategy to protect people in low- and middle-income countries from typhoid.[13] In 2018 phase 2 clinical trials began on the Influenza A virus subtype H7N9 vaccine.[14]

In 2019 Neuzil and the Center for Vaccine Development at the University of Maryland School of Medicine announced a seven-year $200 million contract with the National Institute of Allergy and Infectious Diseases.[15] The research program will test seasonal influenza vaccines and will feature clinical trials with populations including pregnant women, children and the elderly.[5] She has spoken about the need for the public to have an influenza vaccine (flu shot), ideally by the end of October.[16][17][18][19]

Alongside her academic positions, Neuzil serves on the World Health Organization Strategic Advisory Group of Experts on Immunization (SAGE) and previously on the advisory group of the Centers for Disease Control and Prevention (CDC).[5]

• Neuzil, K. M. (2000-01-27). "The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in Children". The New England Journal of Medicine. 342 (4): 225–231. doi:10.1056/NEJM200001273420401. PMID 10648763.
• Neuzil, K. M. (1998-12-01). "Impact of Influenza on Acute Cardiopulmonary Hospitalizations in Pregnant Women". American Journal of Epidemiology. 148 (11): 1094–1102. doi:10.1093/oxfordjournals.aje.a009587. PMID 9850132.
• Neuzil, K. M. (2016-10-13). "Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: A randomized controlled trial". Lancet Global Health. 4 (12): e946–e954. doi:10.1016/S2214-109X(16)30200-5. PMC 5118223. PMID 27746226.
• Neuzil, K. M. (2016-10-13). "Efficacy of live attenuated influenza vaccine among children in Senegal: A randomised trial". Lancet Global Health. 4 (12): e955–e965. doi:10.1016/S2214-109X(16)30201-7. PMC 5118222. PMID 27746224.
• Neuzil, K. M. (2016-06-01). "Non-interference of rotavirus vaccine with measles-rubella vaccine at 9months and improvements in anti-rotavirus immunity: A randomized trial". Journal of Infectious Diseases. 213 (11): 1686–93. doi:10.1093/infdis/jiw024. PMC 4857472. PMID 26823338.

Neuzil serves on the editorial board of Vaccine: X[23] and npj Vaccine.[24]

Neuzil is married with three children.[25]